Tag: preventive vaccines market analysis

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

#Preventive Vaccines Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?#_x000D_

The preventive vaccines market size has experienced strong growth in recent years. It is projected to expand from $83 billion in 2025 to $90.33 billion in 2026, at a compound annual growth rate (CAGR) of 8.8%. The growth observed in the historic period can be attributed to the eradication and control of infectious diseases, government-led vaccination initiatives, rising public health awareness, the establishment of global immunization programs, and increased funding from international health organizations._x000D_

_x000D_

The preventive vaccines market is projected to experience robust expansion over the coming years, reaching a valuation of $131.27 billion in 2030, driven by a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period is fueled by several factors, including the advancement of next-generation vaccine technologies, the increasing global population and urbanization, enhanced outbreak readiness efforts, the broadening of adult immunization campaigns, and a rise in public–private collaborations for vaccine development. Key trends expected during this period involve the extension of national immunization programs, a heightened emphasis on preventive healthcare and disease management, growing demand for both pediatric and geriatric vaccinations, an increase in the development of combination and multivalent vaccines, and improvements in cold chain and vaccine storage facilities._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=28600657&type=smp&name=Preventive%20Vaccines%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Preventive Vaccines Market Industry Drivers: What’s Behind The Revenue Growth?#_x000D_

The rising occurrence of infectious diseases is anticipated to boost the expansion of the preventive vaccines market in the future. These diseases are conditions caused by harmful microorganisms like bacteria, viruses, fungi, or parasites, capable of spreading between individuals or via the environment. Their growing prevalence stems from factors such as increased urbanization, international travel, and antimicrobial resistance, which contribute to the quicker dissemination and greater difficulty in managing infections. Preventive vaccines play a crucial role in managing infectious diseases by priming the immune system to identify and combat pathogens prior to infection, consequently lowering disease rates and spread. As an example, the World Health Organization, an intergovernmental body based in Switzerland, reported in 2024 that global newly diagnosed TB (tuberculosis) cases hit 8.2 million in 2023, an increase from 7.5 million in 2022. Consequently, the expanding occurrence of infectious diseases is propelling the growth of the preventive vaccines market._x000D_

_x000D_

#Preventive Vaccines Market Segments: Where Is Growth Concentrated?#_x000D_

The preventive vaccines market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines_x000D_

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types_x000D_

3) By Age Group: Pediatric, Adult, Geriatric_x000D_

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels_x000D_

_x000D_

Subsegments:_x000D_

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine_x000D_

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine_x000D_

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine_x000D_

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine_x000D_

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine_x000D_

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines_x000D_

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines_x000D_

_x000D_

#Preventive Vaccines Market Growth Trends: What’s Shaping The Future Outlook?_x000D_

Leading companies within the preventive vaccines sector are prioritizing innovations in vaccine science, particularly advanced mRNA technology platforms. This focus aims to boost vaccine effectiveness, refine safety characteristics, accelerate development and production, and offer wider defense against new strains of infectious illnesses. These sophisticated mRNA technology platforms represent state-of-the-art techniques utilizing messenger RNA to direct cellular protein synthesis, thereby initiating a precise immunological reaction. As an illustration, in March 2025, Moderna Inc., a biotechnology firm located in the US, declared FDA clearance for mRNA-1283 (mNEXSPIKE), which is a novel COVID-19 vaccine. Its authorization covers adults 65 and older, alongside individuals aged 12–64 who possess at least one risk factor as specified by the CDC. The introduction of mNEXSPIKE signifies a major stride in the evolution of next-generation mRNA vaccine technology, providing enhanced stability and simpler storage requirements when contrasted with previous iterations. This progression is anticipated to improve the availability and distribution of vaccines, especially within marginalized and distant regions._x000D_

_x000D_

#Preventive Vaccines Market Key Participants And Competitive Landscape#_x000D_

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd. _x000D_

_x000D_

#View The Full Preventive Vaccines Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Preventive Vaccines Market Regional Outlook: Where Is Opportunity Concentrated?#_x000D_

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Preventive Vaccines Market Expected To Reach $131.26 Billion By 2030 At 9.8% CAGR

The market for preventive vaccines has experienced robust expansion over the past few years. Its value is projected to rise from $83 billion in 2025 to $90.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. This historic period’s growth was largely driven by efforts to eradicate and manage infectious diseases, vaccination programs spearheaded by governments, heightened public awareness of health issues, the creation of worldwide immunization campaigns, and greater financial support from global health organizations.

The preventive vaccines market is projected to experience robust expansion over the coming years, reaching an estimated value of $131.27 billion by 2030, with a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period is driven by factors such as the advancement of next-generation vaccine technologies, a growing global population coupled with urban expansion, heightened initiatives aimed at outbreak preparedness, the broadening of adult immunization programs, and a rise in collaborative efforts between public and private sectors in vaccine development. Key trends shaping the market outlook include the widening reach of national immunization campaigns, an increased emphasis on preventive healthcare and disease management, a greater need for vaccines targeting children and the elderly, the development of combination and multivalent vaccines, and improvements in cold chain logistics and storage infrastructure.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Preventive Vaccines Market Opportunity Drivers: What Is Creating New Revenue Potential?

The anticipated expansion of the preventive vaccines market is set to be driven by the growing frequency of infectious diseases. These diseases are caused by pathogenic microorganisms like bacteria, viruses, fungi, or parasites, which can spread between individuals or via environmental factors. Their rising occurrence is fueled by accelerating urbanization, global travel, and antimicrobial resistance, which speed up transmission and complicate containment efforts. Preventive vaccines combat these conditions by priming the immune system to detect and attack pathogens prior to infection, thus lowering case numbers and interrupting spread. As an example, the 2024 report from the World Health Organization, a Switzerland-based intergovernmental body, indicated that newly diagnosed tuberculosis (TB) cases worldwide hit 8.2 million in 2023, up from 7.5 million the previous year. Consequently, the heightened incidence of infectious diseases is fueling growth in the preventive vaccines market.

Preventive Vaccines Market Segment Landscape: Which Areas Lead Market Development?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

Preventive Vaccines Market Innovation Trends Driving Future Development

Leading players in the preventive vaccines market are increasingly investing in innovative vaccine technologies, particularly advanced mRNA platforms, to boost efficacy, improve safety, simplify storage requirements, accelerate production timelines, and offer expanded protection against new strains of infectious diseases. These advanced mRNA platforms utilize messenger RNA to direct cells in generating specific proteins, which in turn prompts a precise immune reaction. A notable example occurred in March 2025, when Moderna Inc., a biotechnology firm based in the United States, secured FDA approval for mRNA-1283, marketed as mNEXSPIKE, a novel COVID-19 vaccine. This vaccine is approved for adults aged 65 and older, as well as individuals between 12 and 64 years old who have at least one risk factor identified by the CDC. The introduction of mNEXSPIKE represents a major milestone in next-generation mRNA vaccine development, featuring enhanced stability and simpler storage conditions relative to previous formulations. Consequently, this breakthrough is anticipated to improve vaccine availability and distribution, especially in underserved and isolated regions.

Preventive Vaccines Market Industry Leaders And Market Competition

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Access The Complete Preventive Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Preventive Vaccines Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Preventive Vaccines Market?

The market for preventive vaccines has seen robust expansion recently. This market is projected to expand from $83 billion in 2025 to reach $90.33 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.8%. Historically, this growth has been driven by factors such as the successful eradication and management of infectious diseases, various government-led vaccination campaigns, heightened public health consciousness, the establishment of worldwide immunization schemes, and increased financial contributions from international health bodies.

The preventive vaccines market size is projected to experience robust expansion over the next few years. It is expected to reach $131.27 billion in 2030, growing at a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period is attributable to several factors, including the evolution of next-generation vaccine platforms, an increasing global population and urbanization, heightened outbreak preparedness initiatives, the enlargement of adult immunization programs, and a rise in public-private partnerships focused on vaccine development. Prominent trends observed within this period encompass the extension of national immunization programs, a stronger emphasis on preventive healthcare and disease control, a growing need for pediatric and geriatric vaccinations, an increase in combination and multivalent vaccines, and the reinforcement of cold chain and vaccine storage infrastructure.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

What Important Drivers Are Powering The Preventive Vaccines Market Growth?

The future expansion of the preventive vaccines market is anticipated to be fueled by the rising occurrence of infectious diseases. These diseases are defined as ailments resulting from pathogenic microorganisms, including bacteria, viruses, fungi, or parasites, capable of spreading among individuals or via environmental factors. Key contributors to this surge in infectious disease prevalence include heightened urbanization, extensive global travel, and growing antimicrobial resistance, all of which contribute to quicker dissemination and greater difficulty in managing infections. Preventive vaccines play a crucial role in managing infectious diseases by priming the immune system to identify and combat pathogens prior to the onset of infection, thus decreasing the occurrence and spread of illness. An illustrative example is the report from 2024 by the World Health Organization, a Switzerland-based intergovernmental body, which indicated that newly identified global cases of TB (tuberculosis) totaled 8.2 million in 2023, up from 7.5 million in 2022. Consequently, the escalating incidence of infectious diseases is a primary catalyst for the expansion of the preventive vaccines market.

What Are The Major Segment Categories Within The Preventive Vaccines Market?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

What Trends Are Influencing The Preventive Vaccines Market Outlook?

Leading companies in the preventive vaccines market are dedicating efforts to progress in vaccine technology, notably advanced mRNA technology platforms. This focus aims to boost vaccine effectiveness, refine safety profiles, enable quicker development and manufacturing processes, and deliver broader protection against novel variants of infectious diseases. Advanced mRNA technology platforms denote innovative methodologies that utilize messenger RNA to guide cells in producing specific proteins, thereby initiating a targeted immune response. For instance, in March 2025, Moderna Inc., a US-based biotechnology company, announced that mRNA-1283 (mNEXSPIKE), a new COVID-19 vaccine, received FDA approval. This vaccine is authorized for adults aged 65 and older and for individuals aged 12–64 who have one or more risk factors as defined by the CDC. The debut of mNEXSPIKE represents a considerable stride in next-generation mRNA vaccine technology, offering superior stability and easier storage conditions compared to earlier versions. This advancement is expected to improve vaccine accessibility and distribution, especially in remote and underserved regions.

Which Firms Are Competing In The Preventive Vaccines Market?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Access The Complete Preventive Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Which Regional Market Leads The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Preventive Vaccines Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2026, By The Business Research Company

Adult Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Travel Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Preventive Vaccines Market Expected To Scale Between 2026 And 2030?

The preventive vaccines market size has demonstrated strong growth in recent years. This market is set to expand from $83 billion in 2025 to $90.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. Factors contributing to its historical growth include the successful eradication and control of infectious diseases, government-led vaccination campaigns, increasing public health awareness, the establishment of global immunization programs, and augmented funding from international health organizations.

The preventive vaccines market is anticipated to experience robust expansion over the coming years. By 2030, its value is projected to reach $131.27 billion, exhibiting a compound annual growth rate (CAGR) of 9.8%. This expansion during the forecast period is fueled by factors such as the advancement of next-generation vaccine technologies, the increasing global population and urban development, heightened initiatives for outbreak preparedness, the broadening of adult immunization schemes, and the proliferation of public-private collaborations in vaccine creation. Key developments expected during this period involve the broadening of national immunization strategies, a heightened emphasis on proactive healthcare and disease management, a growing need for vaccinations for both children and the elderly, an increase in the adoption of combination and multivalent vaccines, and improvements in cold chain and vaccine storage infrastructure.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Which Key Factors Are Driving The Preventive Vaccines Market Growth?

The growing incidence of infectious diseases is poised to fuel the expansion of the preventive vaccines market. These diseases originate from pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, capable of transmission between individuals or through the surroundings. The increasing prevalence of these infections is exacerbated by factors including heightened urbanization, international travel, and antimicrobial resistance, which collectively enable quicker dissemination and more challenging containment. Preventive vaccines work by stimulating the immune system to recognize and fight off pathogens before an infection takes hold, thereby diminishing disease occurrence and transmission. For example, in 2024, the World Health Organization reported that new global cases of TB (tuberculosis) reached 8.2 million in 2023, marking an increase from 7.5 million in 2022. Consequently, the rising occurrence of infectious diseases is a key driver for the growth of the preventive vaccines market.

Which Segment Classifications Are Used In The Preventive Vaccines Market Segment Analysis?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

Which Trends Are Shaping Growth In The Preventive Vaccines Market?

Leading companies within the preventive vaccines market are prioritizing innovations in vaccine technology, including advanced mRNA technology platforms, to boost vaccine efficacy, enhance safety profiles, accelerate development and manufacturing processes, and offer broader protection against evolving variants of infectious diseases. These advanced mRNA technology platforms represent cutting-edge methodologies that utilize messenger RNA to instruct cells to generate specific proteins, thereby initiating a targeted immune response. For example, in March 2025, Moderna Inc., a US-based biotechnology company, announced FDA approval for mRNA-1283 (mNEXSPIKE), its new COVID-19 vaccine. This vaccine is authorized for adults aged 65 and older and individuals aged 12–64 who have one or more CDC-defined risk factors. The release of mNEXSPIKE signifies a notable leap forward in next-generation mRNA vaccine technology, offering superior stability and simplified storage compared to previous versions. This progress is projected to improve vaccine accessibility and distribution, especially in underserved and remote areas.

Which Firms Are Contributing To The Preventive Vaccines Market Ecosystem?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Get The Full Preventive Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Which Region Holds The Highest Market Share In The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Preventive Vaccines Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2026, By The Business Research Company

Adult Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Travel Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Preventive Vaccines Market Over The Period 2026–2030?

The preventive vaccines market has experienced substantial expansion in recent years. Projections indicate it will grow from $83 billion in 2025 to $90.33 billion in 2026, at a compound annual growth rate (CAGR) of 8.8%. Historically, this growth has been fueled by factors such as the successful eradication and control of infectious diseases, various government-led vaccination efforts, a rise in public health consciousness, the establishment of worldwide immunization programs, and enhanced funding from global health organizations.

The preventive vaccines market is projected to experience robust expansion over the coming years. It is anticipated to grow to $131.27 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.8%. This growth during the forecast period is primarily driven by the advancement of next-generation vaccine platforms, an increasing global population and urbanization, intensified outbreak preparedness initiatives, the expansion of adult immunization programs, and the rising number of public–private partnerships in vaccine development. Noteworthy trends in the forecast period include the broadening of national immunization programs, a greater emphasis on preventive healthcare and disease control, an increasing demand for pediatric and geriatric vaccination, the proliferation of combination and multivalent vaccines, and the strengthening of cold chain and vaccine storage infrastructure.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Which Economic Or Industry Drivers Are Impacting The Preventive Vaccines Market?

The growing incidence of infectious diseases is anticipated to boost the expansion of the preventive vaccines market in the future. Infectious diseases are conditions resulting from pathogenic microorganisms like bacteria, viruses, fungi, or parasites, which can spread between individuals or via environmental contact. This increase in infectious disease prevalence stems from factors such as heightened urbanization, international travel, and antimicrobial resistance, all of which contribute to more rapid transmission and greater difficulty in managing infections. Preventive vaccines aid in managing infectious diseases by activating the immune system to identify and combat pathogens prior to infection, consequently lowering disease rates and spread. As an example, in 2024, the World Health Organization, an intergovernmental body located in Switzerland, disclosed that global new TB (tuberculosis) diagnoses amounted to 8.2 million in 2023, up from 7.5 million in 2022. Consequently, the rising prevalence of infectious diseases is fueling the expansion of the preventive vaccines market.

How Is The Preventive Vaccines Market Divided Into Its Major Segments?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

How Are Trends Transforming The Preventive Vaccines Market Landscape?

Leading companies in the preventive vaccines market are focusing on innovations in vaccine technology, such as sophisticated mRNA platforms, to enhance vaccine efficacy, improve safety profiles, enable faster development and manufacturing, and provide broader protection against emerging variants of infectious diseases. Advanced mRNA technology platforms involve cutting-edge methods that use messenger RNA to instruct cells to produce specific proteins, initiating a targeted immune response. For instance, in March 2025, Moderna Inc., a US-based biotechnology company, announced FDA approval for mRNA-1283 (mNEXSPIKE), a new COVID-19 vaccine. It is authorized for adults aged 65 and older and individuals aged 12–64 with one or more CDC-defined risk factors. The launch of mNEXSPIKE marks a significant advancement in next-generation mRNA vaccine technology, offering improved stability and ease of storage compared to earlier versions. This development is expected to enhance vaccine accessibility and distribution, particularly in underserved and remote areas.

Who Are The Prominent Organizations Shaping The Preventive Vaccines Market?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Read the full preventive vaccines market report here:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

What Are The Top-Performing Regions Within The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Preventive Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24667&type=smp

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2026, By The Business Research Company

Adult Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Travel Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Preventive Vaccines Market Over The Period 2026–2030?

The preventive vaccines market has experienced substantial expansion in recent years. Projections indicate it will grow from $83 billion in 2025 to $90.33 billion in 2026, at a compound annual growth rate (CAGR) of 8.8%. Historically, this growth has been fueled by factors such as the successful eradication and control of infectious diseases, various government-led vaccination efforts, a rise in public health consciousness, the establishment of worldwide immunization programs, and enhanced funding from global health organizations.

The preventive vaccines market is projected to experience robust expansion over the coming years. It is anticipated to grow to $131.27 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.8%. This growth during the forecast period is primarily driven by the advancement of next-generation vaccine platforms, an increasing global population and urbanization, intensified outbreak preparedness initiatives, the expansion of adult immunization programs, and the rising number of public–private partnerships in vaccine development. Noteworthy trends in the forecast period include the broadening of national immunization programs, a greater emphasis on preventive healthcare and disease control, an increasing demand for pediatric and geriatric vaccination, the proliferation of combination and multivalent vaccines, and the strengthening of cold chain and vaccine storage infrastructure.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Which Economic Or Industry Drivers Are Impacting The Preventive Vaccines Market?

The growing incidence of infectious diseases is anticipated to boost the expansion of the preventive vaccines market in the future. Infectious diseases are conditions resulting from pathogenic microorganisms like bacteria, viruses, fungi, or parasites, which can spread between individuals or via environmental contact. This increase in infectious disease prevalence stems from factors such as heightened urbanization, international travel, and antimicrobial resistance, all of which contribute to more rapid transmission and greater difficulty in managing infections. Preventive vaccines aid in managing infectious diseases by activating the immune system to identify and combat pathogens prior to infection, consequently lowering disease rates and spread. As an example, in 2024, the World Health Organization, an intergovernmental body located in Switzerland, disclosed that global new TB (tuberculosis) diagnoses amounted to 8.2 million in 2023, up from 7.5 million in 2022. Consequently, the rising prevalence of infectious diseases is fueling the expansion of the preventive vaccines market.

How Is The Preventive Vaccines Market Divided Into Its Major Segments?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

How Are Trends Transforming The Preventive Vaccines Market Landscape?

Leading companies in the preventive vaccines market are focusing on innovations in vaccine technology, such as sophisticated mRNA platforms, to enhance vaccine efficacy, improve safety profiles, enable faster development and manufacturing, and provide broader protection against emerging variants of infectious diseases. Advanced mRNA technology platforms involve cutting-edge methods that use messenger RNA to instruct cells to produce specific proteins, initiating a targeted immune response. For instance, in March 2025, Moderna Inc., a US-based biotechnology company, announced FDA approval for mRNA-1283 (mNEXSPIKE), a new COVID-19 vaccine. It is authorized for adults aged 65 and older and individuals aged 12–64 with one or more CDC-defined risk factors. The launch of mNEXSPIKE marks a significant advancement in next-generation mRNA vaccine technology, offering improved stability and ease of storage compared to earlier versions. This development is expected to enhance vaccine accessibility and distribution, particularly in underserved and remote areas.

Who Are The Prominent Organizations Shaping The Preventive Vaccines Market?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Read the full preventive vaccines market report here:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

What Are The Top-Performing Regions Within The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Preventive Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24667&type=smp

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2026, By The Business Research Company

Adult Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Travel Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Preventive Vaccines Market Over The Period 2026–2030?

The preventive vaccines market has experienced substantial expansion in recent years. Projections indicate it will grow from $83 billion in 2025 to $90.33 billion in 2026, at a compound annual growth rate (CAGR) of 8.8%. Historically, this growth has been fueled by factors such as the successful eradication and control of infectious diseases, various government-led vaccination efforts, a rise in public health consciousness, the establishment of worldwide immunization programs, and enhanced funding from global health organizations.

The preventive vaccines market is projected to experience robust expansion over the coming years. It is anticipated to grow to $131.27 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.8%. This growth during the forecast period is primarily driven by the advancement of next-generation vaccine platforms, an increasing global population and urbanization, intensified outbreak preparedness initiatives, the expansion of adult immunization programs, and the rising number of public–private partnerships in vaccine development. Noteworthy trends in the forecast period include the broadening of national immunization programs, a greater emphasis on preventive healthcare and disease control, an increasing demand for pediatric and geriatric vaccination, the proliferation of combination and multivalent vaccines, and the strengthening of cold chain and vaccine storage infrastructure.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Which Economic Or Industry Drivers Are Impacting The Preventive Vaccines Market?

The growing incidence of infectious diseases is anticipated to boost the expansion of the preventive vaccines market in the future. Infectious diseases are conditions resulting from pathogenic microorganisms like bacteria, viruses, fungi, or parasites, which can spread between individuals or via environmental contact. This increase in infectious disease prevalence stems from factors such as heightened urbanization, international travel, and antimicrobial resistance, all of which contribute to more rapid transmission and greater difficulty in managing infections. Preventive vaccines aid in managing infectious diseases by activating the immune system to identify and combat pathogens prior to infection, consequently lowering disease rates and spread. As an example, in 2024, the World Health Organization, an intergovernmental body located in Switzerland, disclosed that global new TB (tuberculosis) diagnoses amounted to 8.2 million in 2023, up from 7.5 million in 2022. Consequently, the rising prevalence of infectious diseases is fueling the expansion of the preventive vaccines market.

How Is The Preventive Vaccines Market Divided Into Its Major Segments?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

How Are Trends Transforming The Preventive Vaccines Market Landscape?

Leading companies in the preventive vaccines market are focusing on innovations in vaccine technology, such as sophisticated mRNA platforms, to enhance vaccine efficacy, improve safety profiles, enable faster development and manufacturing, and provide broader protection against emerging variants of infectious diseases. Advanced mRNA technology platforms involve cutting-edge methods that use messenger RNA to instruct cells to produce specific proteins, initiating a targeted immune response. For instance, in March 2025, Moderna Inc., a US-based biotechnology company, announced FDA approval for mRNA-1283 (mNEXSPIKE), a new COVID-19 vaccine. It is authorized for adults aged 65 and older and individuals aged 12–64 with one or more CDC-defined risk factors. The launch of mNEXSPIKE marks a significant advancement in next-generation mRNA vaccine technology, offering improved stability and ease of storage compared to earlier versions. This development is expected to enhance vaccine accessibility and distribution, particularly in underserved and remote areas.

Who Are The Prominent Organizations Shaping The Preventive Vaccines Market?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Read the full preventive vaccines market report here:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

What Are The Top-Performing Regions Within The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Preventive Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24667&type=smp

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2026, By The Business Research Company

Adult Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Travel Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the preventive vaccines market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Preventive Vaccines Market’s size between 2026 and 2030?

The preventive vaccines market has shown substantial growth in recent years. It is anticipated to increase from $83 billion in 2025 to $90.33 billion in 2026, progressing at a compound annual growth rate (CAGR) of 8.8%. This historical expansion can be linked to the successful eradication and management of infectious diseases, governmental vaccination efforts, heightened public health awareness, the creation of global immunization schemes, and increased financial contributions from international health bodies.

The preventive vaccines market is anticipated to experience robust expansion in the coming years. Projections indicate it will reach $131.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. This expansion during the forecast period is primarily driven by factors such as the advancement of next-generation vaccine platforms, the increasing global population and urbanization, heightened initiatives for outbreak preparedness, the broadening of adult immunization programs, and the growth of public–private collaborations in vaccine development. Key trends expected over the same period encompass the broadening of national immunization programs, a growing emphasis on preventive healthcare and disease control, an escalating demand for both pediatric and geriatric vaccinations, the development of more combination and multivalent vaccines, and the reinforcement of cold chain and vaccine storage infrastructure.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Which Drivers Are Shaping Strategic Decisions In The Preventive Vaccines Market?

The future expansion of the preventive vaccines market is anticipated to be significantly driven by the rising occurrence of infectious diseases. These illnesses are characterized by their origin in pathogenic microorganisms like bacteria, viruses, fungi, or parasites, capable of spreading between individuals or via environmental vectors. Factors such as growing urbanization, international travel, and antimicrobial resistance contribute to the heightened prevalence of infectious diseases, making their spread quicker and control more challenging. Preventive vaccines play a crucial role in managing these diseases by activating the immune system to identify and combat pathogens prior to infection, thus lowering both the incidence and transmission rates. As an illustration, in 2024, the World Health Organization, an intergovernmental organization located in Switzerland, disclosed that global new diagnoses of TB (tuberculosis) cases hit 8.2 million in 2023, up from 7.5 million in 2022. Consequently, the increasing frequency of infectious diseases is a primary catalyst for the growth observed in the preventive vaccines market.

What Segment Classifications Make Up The Preventive Vaccines Market?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

Which Market Trends Are Opening Growth Opportunities In The Preventive Vaccines Market?

Leading companies within the preventive vaccines market are directing their efforts towards breakthroughs in vaccine technology, including sophisticated mRNA technology platforms. This focus aims to boost vaccine effectiveness, refine safety aspects, accelerate development and manufacturing processes, and offer more extensive protection against novel variants of infectious diseases. These advanced mRNA technology platforms represent innovative approaches that utilize messenger RNA to guide cells in creating particular proteins, thereby stimulating a precise immune response. As an illustration, in March 2025, Moderna Inc., a US-based biotechnology firm, declared that its new COVID-19 vaccine, mRNA-1283 (mNEXSPIKE), received FDA approval. This vaccine is approved for adults aged 65 and older, as well as for individuals aged 12–64 who possess one or more risk factors as defined by the CDC. The introduction of mNEXSPIKE signifies a major leap forward in next-generation mRNA vaccine technology, providing enhanced stability and simpler storage requirements when contrasted with preceding iterations. This progression is anticipated to boost vaccine accessibility and distribution, especially benefiting underserved and remote communities.

Which Leading Companies Dominate The Preventive Vaccines Market Share?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

How Does The Preventive Vaccines Market Perform Across Major Global Regions?

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Preventive Vaccines Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24667&type=smp

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2026, By The Business Research Company

Adult Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Travel Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Preventive Vaccines Industry Expected To Reach By 2029, Starting From 2025 Levels?

The preventive vaccines market size has experienced robust growth in recent years. This market is projected to expand from $75.94 billion in 2024 to $81.39 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Historically, this expansion has been driven by increasing government funding, rising awareness of infectious diseases, a rise in global immunization programs, increasing technological advancements in vaccine development, and rising demand for childhood immunization.

The preventive vaccines market is poised for significant expansion in the coming years. Its valuation is projected to reach $106.47 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. This anticipated growth during the forecast period is fueled by several factors, including escalating investment in vaccine research, the increasing occurrence of infectious diseases, a rising need for personalized vaccines, more government initiatives and backing, and the wider uptake of cutting-edge vaccine technologies. Key trends anticipated within this period encompass progress in mRNA vaccine technology, the development of sophisticated delivery systems, breakthroughs in nanoparticle-based vaccines, the incorporation of artificial intelligence into vaccine research, and improvements in cold chain logistics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Which Drivers Are Shaping The Preventive Vaccines Industry’s Market Share?

The anticipated expansion of the preventive vaccines market is linked to the growing occurrence of infectious diseases. These diseases are defined as ailments resulting from pathogenic microorganisms, including bacteria, viruses, fungi, or parasites, capable of spreading between individuals or via the surroundings. Factors like escalating urbanization, widespread global travel, and resistance to antimicrobials contribute to the heightened incidence of infectious diseases, making their spread quicker and control more challenging. Preventive vaccines assist in managing infectious diseases by prompting the immune system to identify and combat pathogens prior to infection, consequently lowering the frequency and spread of illnesses. As an illustration, a report in July 2024 from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2022, infectious diseases were responsible for more than 15,770 fatalities in Australia, with lower respiratory infections comprising a third of these non-notifiable disease-related deaths. Consequently, the rising occurrence of infectious diseases is a key factor propelling the expansion of the preventive vaccines market.

What Are The Major Segment Categories Driving The Preventive Vaccines Market Growth?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

What Long-Term Trends Will Shape The Future Growth Of The Preventive Vaccines Industry?

Leading companies within the preventive vaccines market are concentrating on progress in vaccine technology, including advanced mRNA technology platforms, to boost vaccine effectiveness, improve safety profiles, facilitate quicker development and production, and offer broader defense against evolving variants of infectious diseases. Advanced mRNA technology platforms are sophisticated techniques employing messenger RNA to instruct cells to generate specific proteins, initiating a targeted immune response. For example, in March 2025, Moderna Inc., a US-based biotechnology firm, declared FDA clearance for mNEXSPIKE (mRNA-1283), a novel COVID-19 vaccine. It is approved for adults aged 65 and older and individuals aged 12–64 who have one or more CDC-defined risk factors. The introduction of mNEXSPIKE represents a considerable leap in next-generation mRNA vaccine technology, providing enhanced stability and simpler storage compared to previous iterations. This innovation is anticipated to improve vaccine availability and delivery, especially in underserved and remote regions.

Who Are The Primary Competitors In The Global Preventive Vaccines Market?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Preventive Vaccines Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24667&type=smp

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2025, By The Business Research Company

Probiotics Dietary Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/probiotics-dietary-supplements-global-market-report

Probiotics Food And Cosmetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/probiotics-food-and-cosmetics-global-market-report

Animal Antibiotics And Antimicrobials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/animal-antibiotics-and-antimicrobials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Preventive Vaccines Industry?

The market size for preventive vaccines has seen significant expansion in the past years. The market is projected to escalate from $75.94 billion in 2024 to a whopping $81.39 billion in 2025, yielding a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this historic growth include heightened government support, increased consciousness about infectious diseases, an upsurge in worldwide immunization initiatives, advancements in vaccine technology, and a surge in the requirement for childhood vaccination.

The market for preventive vaccines is predicted to witness considerable expansion in the upcoming years, with an expected value of $106.47 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. This growth within the prediction span can be linked to the escalated investment in vaccine research, the increasing occurrence of infectious diseases, the soaring demand for tailor-made vaccines, amplified government initiatives and backing, along with the increasing incorporation of advanced vaccine technologies. The forecast period witnesses various key trends, inclusive of the progression in mRNA vaccine technology, the development of advanced delivery systems, the emergence of innovative nanoparticle-based vaccines, engagement of artificial intelligence in vaccine research, and the rise in cold chain logistics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

#Which Factors Are Currently Driving The Growth Of The Preventive Vaccines Market?

The surge in infectious diseases is predicted to drive the expansion of the preventive vaccines market. These diseases are illnesses caused by microorganisms like bacteria, viruses, fungi or parasites, which are easily transmitable from one person to another or through environmental mediums. The increase in infectious diseases is primarily due to factors such as growing urbanization, international travel, and antimicrobial resistance. These factors contribute to the quick spread and difficulties in containment of these infections. Vaccines for prevention aid in controlling these diseases as they stimulate the immune system to identify and counteract pathogens before they get a chance to infect, this decreases disease occurrence and transmission. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency in Australia, declared that in 2022, infectious diseases resulted in over 15,770 fatalities in Australia. Of these, a third were due to lower respiratory infections which are non-notifiable disease deaths. This rise in the prevalence of infectious diseases drives the expansion of the preventive vaccines market.

How Is The Global Preventive Vaccines Market Structured In Terms Of Segments?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

What Trends Are Currently Influencing Growth In The Preventive Vaccines Market?

Major preventive vaccines market players are prioritizing advancements in vaccine technology, including advanced mRNA technology platforms. These innovations aim to improve the efficacy and safety of vaccines, expedite their production and development, and offer a more comprehensive defense against emerging infectious disease variants. Advanced mRNA technology platforms use messenger RNA to guide cells to create specific proteins, thus stimulating a targeted immune reaction. In March 2025, a notable example occurred when Moderna Inc., a biotech firm based in the United States, received FDA approval for their new COVID-19 vaccine mNEXSPIKE (mRNA-1283), designed for adults 65 years or older and 12 to 64 years old individuals who have one or more risk factors identified by the CDC. The release of mNEXSPIKE represents a huge step forward in the next wave of mRNA vaccine technology, as it offers superior stability and storage ease compared to previous models. This move is set to raise vaccine accessibility and distribution, especially in remote and underprivileged areas.

Who Are The Main Participants Shaping The Preventive Vaccines Market Landscape?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Which Region Currently Holds The Largest Share In The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24667&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model